Company / Current Assets
Vistagen Therapeutics, Inc. Current Assets History
FY2011-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$17.5M
FY2023
5-year range
$3.4M / $104.1M
FY2019-FY2023
Trend
-75.3%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $104M to $18M over the past 2 years.
Based on SEC 10-K filings.
$18M in FY2023 with a 5-year CAGR of +9.7%.
Declined from $104M to $18M over the past 2 years.
Current Assets over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +9.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +9.7%, indicating consistent growth.
- In FY2023, current assets decreased 75.3% year-over-year.
- Peak current assets was recorded in FY2021.
- Lowest current assets in the period was in FY2012.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -7.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | $17.5M | -75.3% |
| FY2022 | $71.0M | -31.8% |
| FY2021 | $104.1M | +844.5% |
| FY2018 | $11.0M | +226.3% |
| FY2017 | $3.4M | +402.8% |
| FY2014 | $671.8K | +182.2% |
| FY2012 | $238.1K | +0.0% |
| FY2011 | $238.1K | - |
As of FY2023 · SEC 10-K · Updated Jun 28, 2026